Large Cell Neuroendocrine Carcinoma (LCNEC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Large Cell Neuroendocrine Carcinoma (LCNEC) Market Outlook

Thelansis’s “Large Cell Neuroendocrine Carcinoma (LCNEC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Large Cell Neuroendocrine Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Large Cell Neuroendocrine Carcinoma (LCNEC) Overview

Large Cell Neuroendocrine Carcinoma (LCNEC) is a distinct subgroup of high-grade neuroendocrine neoplasms, exhibiting a rare occurrence throughout the human body. Although the lung is identified as the most prevalent primary site, LCNEC has been reported in the gastrointestinal tract and an array of other locations, including the cervix, uterus, kidney, bladder, prostate, pharynx, larynx, and numerous other primary sites. Its aggressive nature and rapid growth characterize LCNEC, drawing parallels with Small Cell Lung Cancer (SCLC). The majority of LCNEC cases originate in the lungs, with pulmonary LCNEC accounting for 2 to 3.5% of all lung cancer cases. LCNEC is a high-grade carcinoma that exhibits neuroendocrine architectural features, including the formation of rosettes, trabeculae, organoid nests, or perilobular palisading patterns, more than 10 mitoses per 2 mm2, and the expression of neuroendocrine immunohistochemical markers. The current World Health Organization (WHO) criteria for LCNEC diagnosis encompass:

1. Neuroendocrine morphology (trabeculae, palisading, organoid nesting, and/or rosette formation)
2. A high proliferation rate (>10 mitoses per 10 high-power fields)
3. Extensive geographic necrosis
4. Immunohistochemical (IHC) expression of at least one neuroendocrine marker (chromogranin-A, synaptophysin, NCAM/CD56)

The cytological diagnosis of LCNEC and its differentiation from SCLC can pose significant challenges. However, two critical clinical distinctions from SCLC include (i) a higher likelihood of presenting with early-stage disease (~25% of cases) and (ii) a greater propensity for primary lesions to be peripheral. Despite LCNEC distinction from other subtypes of Non-Small Cell Lung Cancer (NSCLC) or SCLC, no standard of care (SOC) currently exists.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: